Work

A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2579

Authors: Manish R. Patel, David S. Hong, Johanna C. Bendell, Suzanne Fields Jones, Erika Paige Hamilton, Vivek Subbiah, Daniel D. Karp, Judy Sing-Zan Wang, Raid Aljumaily, Scott Hynes, Rod Decker, Michele Niland, Xuejing Aimee Wang, Aimee K. Lin, Kathleen N. Moore

Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, Johns Hopkins Medicine, University of Oklahoma Medical Center, Eli Lilly (United States), University of Oklahoma Health Sciences Center

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890083017

Cites:

Cited by: 5

Related to: 10